These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 4046841)

  • 1. Effect of clofibrate and colestipol singly and in combination on plasma lipids and lipoproteins in type III hyperlipoproteinemia.
    Hoogwerf BJ; Peters JR; Frantz ID; Hunninghake DB
    Metabolism; 1985 Oct; 34(10):978-81. PubMed ID: 4046841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of colestipol and clofibrate, singly and in combination, on plasma lipid and lipoproteins in type IIb hyperlipoproteinemia.
    Hunninghake DB; Bell C; Olson L
    Metabolism; 1981 Jun; 30(6):610-5. PubMed ID: 7231198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of colestipol and clofibrate on plasma lipid and lipoproteins in type IIa hyperlipoproteinemia.
    Hunninghake DB; Probstfield JL; Crow LO; Isaacson SO
    Metabolism; 1981 Jun; 30(6):605-9. PubMed ID: 7231197
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of colestipol, clofibrate, and placebo on plasma lipoproteins of patients with hypercholesterolemia.
    Crouse JR; Grundy SM
    Metabolism; 1981 Feb; 30(2):123-8. PubMed ID: 7464561
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the effects of colestipol hydrochloride and clofibrate on plasma lipids and lipoproteins in the treatment of hypercholesterolemia.
    Seplowitz AH; Smith FR; Berns L; Eder HA; Goodman DS
    Atherosclerosis; 1981 Apr; 39(1):35-43. PubMed ID: 7018502
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clofibrate-induced low density liporotein elevation. Therapeutic implications and treatment by colestipol resin.
    Rose HG; Haft GK; Juliano J
    Atherosclerosis; 1976; 23(3):413-27. PubMed ID: 178325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative efficacy of colestipol and clofibrate in type IIa hyperlipoproteinemia.
    Vecchio TJ; Linden CV; O'Connell MJ; Heilman J
    Arch Intern Med; 1982 Apr; 142(4):721-3. PubMed ID: 7073415
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of bezafibrate and colestipol on LDL-cholesterol, LDL-apolipoprotein B and HDL-cholesterol in hyperlipoproteinaemia.
    Kłosiewicz-Latoszek L; Nowicka G; Szostak WB; Naruszewicz M
    Atherosclerosis; 1987 Feb; 63(2-3):203-9. PubMed ID: 3827981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of type III hyperlipoproteinemia with four different treatment regimens.
    Hoogwerf BJ; Bantle JP; Kuba K; Frantz ID; Hunninghake DB
    Atherosclerosis; 1984; 51(2-3):251-9. PubMed ID: 6588975
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Colestipol, clofibrate, cholestyramine and combination therapy in the treatment of familial hyperbetalipoproteinaemia.
    Stein EA; Heimann KW
    S Afr Med J; 1975 Jul; 49(31):1252-6. PubMed ID: 168650
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative effects of gemfibrozil and clofibrate in type III hyperlipoproteinemia.
    Larsen ML; Illingworth DR; O'Malley JP
    Atherosclerosis; 1994 Apr; 106(2):235-40. PubMed ID: 8060383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of colestipol when combined with clofibrate in the treatment of severe hyperlipidemia. Short-term and long-term studies.
    Lithell H; Vessby B; Boberg J; Hellsing K
    Atherosclerosis; 1980 Oct; 37(2):175-86. PubMed ID: 7000089
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The hypolipidemic effects of lovastatin and clofibrate alone and in combination in patients with type III hyperlipoproteinemia.
    Illingworth DR; O'Malley JP
    Metabolism; 1990 Apr; 39(4):403-9. PubMed ID: 2182974
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma and lipoprotein lipid responses to four hypolipid drugs.
    Hazzard WR; Wahl PW; Gagne C; Applebaum-Bowden D; Warnick GR; Albers JJ
    Lipids; 1984 Feb; 19(2):73-9. PubMed ID: 6708754
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Colestipol, clofibrate, and phytosterols in combined therapy of hyperlipidemia.
    Grundy SM; Mok HY
    J Lab Clin Med; 1977 Feb; 89(2):354-66. PubMed ID: 833472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term trial with colestipol plus clofibrate in familial hypercholesterolemia.
    Fellin R; Baggio G; Briani G; Baiocchi MR; Manzato E; Baldo G; Crepaldi G
    Atherosclerosis; 1978 Feb; 29(2):241-9. PubMed ID: 348207
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fenofibrate and colestipol: effects on serum and lipoprotein lipids and apolipoproteins in familial hypercholesterolaemia.
    Weisweiler P; Merk W; Jacob B; Schwandt P
    Eur J Clin Pharmacol; 1986; 30(2):191-4. PubMed ID: 3709644
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primary hypercholesterolemia: effect of treatment on serum lipids, lipoprotein fractions, cholesterol absorption, sterol balance, and platelet aggregation.
    Briones ER; Steiger D; Palumbo PJ; Kottke BA
    Mayo Clin Proc; 1984 Apr; 59(4):251-7. PubMed ID: 6708603
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of combined diet and colestipol in long-term (7--7 1/2 years) treatment of patients with type II hyperlipoproteinemia.
    Kuo PT; Hayase K; Kostis JB; Moreyra AE
    Circulation; 1979 Feb; 59(2):199-211. PubMed ID: 215338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. "Low dose" colestipol in children, adolescents and young adults with familial hypercholesterolemia.
    Schlierf G; Mrozik K; Heuck CC; Middelhoff G; Oster P; Riesen W; Schellenberg B
    Atherosclerosis; 1982 Jan; 41(1):133-8. PubMed ID: 7073790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.